Wall Street analysts expect TherapeuticsMD Inc (NASDAQ:TXMD) to post earnings per share (EPS) of ($0.10) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for TherapeuticsMD’s earnings. The lowest EPS estimate is ($0.11) and the highest is ($0.08). TherapeuticsMD reported earnings of ($0.11) per share in the same quarter last year, which would indicate a positive year over year growth rate of 9.1%. The firm is expected to report its next earnings report on Tuesday, May 1st.
On average, analysts expect that TherapeuticsMD will report full-year earnings of ($0.40) per share for the current year, with EPS estimates ranging from ($0.69) to $0.18. For the next financial year, analysts anticipate that the business will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.35) to $0.24. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Tuesday, February 20th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $4.66 million. TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. TherapeuticsMD’s revenue for the quarter was down 8.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.12) earnings per share.
A number of equities analysts have recently issued reports on TXMD shares. Deutsche Bank set a $9.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Oppenheimer set a $10.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research report on Wednesday, December 20th. BidaskClub downgraded TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research report on Friday, December 22nd. Finally, Cantor Fitzgerald restated a “buy” rating and set a $28.00 price objective on shares of TherapeuticsMD in a research report on Thursday, December 28th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. TherapeuticsMD presently has an average rating of “Buy” and a consensus price target of $14.50.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its stake in TherapeuticsMD by 4.5% during the fourth quarter. California State Teachers Retirement System now owns 261,142 shares of the company’s stock worth $1,577,000 after purchasing an additional 11,317 shares during the period. Greenwood Capital Associates LLC grew its stake in TherapeuticsMD by 25.9% during the fourth quarter. Greenwood Capital Associates LLC now owns 74,268 shares of the company’s stock worth $449,000 after purchasing an additional 15,300 shares during the period. MANA Advisors LLC acquired a new stake in TherapeuticsMD during the fourth quarter worth approximately $104,000. Paloma Partners Management Co acquired a new stake in TherapeuticsMD during the fourth quarter worth approximately $105,000. Finally, Edge Wealth Management LLC grew its stake in TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock worth $125,000 after purchasing an additional 20,000 shares during the period. 73.31% of the stock is owned by institutional investors and hedge funds.
TherapeuticsMD stock traded up $0.01 during trading hours on Friday, hitting $5.83. The stock had a trading volume of 1,213,257 shares, compared to its average volume of 1,937,715. The company has a market capitalization of $1,237.81, a PE ratio of -15.92 and a beta of 1.36. TherapeuticsMD has a one year low of $3.50 and a one year high of $7.01.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/19/analysts-anticipate-therapeuticsmd-inc-txmd-to-post-0-10-eps.html.
TherapeuticsMD, Inc is a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.